



Hypoxia- and Anoikis-Related lncRNA Signature Defines Molecular Subtypes and Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma [Corrigendum]

Lu X, Wang Y, Yu Y, et al. *J Hepatocell Carcinoma*. 2025;12:2307—2325.

The authors have advised that they neglected to include a funding statement on page 2323 of the published paper. The funding statement should read as follows.

Funding

This study was supported by the National Natural Science Foundation of China (No. 82160829), the Guangxi Zhuang Autonomous Region Natural Science Foundation (Nos. 2025GXNSFDA069035 and 2025GXNSFAA069372), the Project of Inheriting Studio Construction about 2024 Guangxi Famous Traditional Chinese Medicine (No. GZY2024012), the Qihuang High-Level Talent Team Project (No. 2202409), the Guipai Xinglin Top-Talent Project (No. 202202), and the Third Batch of Qihuang High-Level Talent Team Project of Guangxi University of Chinese Medicine (No. 202411).

The authors apologize for this error.

Publish your work in this journal

The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal that offers a platform for the dissemination and study of clinical, translational and basic research findings in this rapidly developing field. Development in areas including, but not limited to, epidemiology, vaccination, hepatitis therapy, pathology and molecular tumor classification and prognostication are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal>

